PHOENIX, May 29, 2018 (GLOBE NEWSWIRE) -- Dr. Mark Day, president and chief executive officer of Bioasis Technologies Inc. (OTCQB:BIOAF) (TSX.V:BTI) (“the Company”), recently spoke with “Stock Day” host Everett Jolly about the company’s undertakings in the neuroscience research and development field.
Bioasis Technologies Inc. is a biopharmaceutical company carrying out research and development of medications to treat a variety of serious neurological disorders. This includes conditions such as brain cancers and neurodegenerative diseases, such as Parkinson’s and Progressive Super Nuclear Palsy (PSNP), complex disorders with no definitive course of treatment.
Dr. Mark Day’s academic background in neuroscience and professional experience with research and business development made him an ideal candidate to take over the company in April 2017. “I’m excited to drive a company like Bioasis forward, because I think it has tremendous potential.” Dr. Day explains further that a major factor in wanting to join Bioasis was his desire to actually make an effective medicine, rather than just conducting research.
Bioasis has developed a proprietary brain delivery technology called the xB3 TM platform, which is designed to deliver therapeutics across the blood-brain barrier (BBB). Dr. Day says the purpose of the BBB is to prevent blood-borne diseases and toxins from getting in to the brain, but it can also prevent treatments from getting to the brain. The purpose of the company’s xB3 platform technology is to bypass the BBB and to make life-saving therapies brain-penetrant. The xB3 platform has shown high efficacy in its ability to shuttle molecules across the BBB and reach its targets within the brain.
Bioasis recently announced the Company’s intention to list on the NASDAQ Exchange as well as a collaboration with WuXi Biologics to develop and manufacture xB3-001, the Company’s lead investigational candidate to treat brain cancer.
The company is currently listed on the TSX Venture Exchange under the ticker symbol BTI and also trades on the OTCQB under the ticker symbol BIOAF. The current share price is U.S. $0.48 per share.
To learn more about blood-brain barrier science, the company’s internal pipeline and business development strategies, listen to the audio of the full interview at the link below.
About Bioasis Technologies, Inc.
Bioasis Technologies, Inc. is a biopharmaceutical company developing xB3, a proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Richmond, British Columbia, Canada with offices in Guilford, Conn., USA.
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Contact:
Uptick Newswire, LLC
Dana Peters, Communications Director
602-441-3474
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/